IMPACT OF CERTOLIZUMAB PEGOL ON QUALITY-ADJUSTED LIFE-YEARS IN TWO INDUCTION AND MAINTENANCE TRIALS IN PATIENTS WITH ACTIVE CROHN’S DISEASE
Tan SC,1 Gerlier LC,2 Brown M1
1UCB, Slough, Berkshire, UK, 2Keyrus Biopharma, Levallois-Perret, France

OBJECTIVES: The efficacy and safety of certolizumab pegol (CZP), a PEGylated anti-TNF, in patients with active Crohn’s disease (CD) have been demonstrated in two 26-week induction and maintenance trials, PRECiSE 1 (Sandborn et al., 2005) and PRECiSE 2 (Schreiber et al., 2005). This analysis evaluated the effect of CZP versus placebo on quality-adjusted life-years (QALYs) for each subject in these trials. METHODS: In PRECiSE 1, patients with active CD received double-blind CZP 400 mg (n = 331) or placebo (n = 328) every 4 weeks after induction. PRECiSE 2 began with an open-label induction period (CZP 400 mg at Weeks 0, 2 and 4). Patients who demonstrated a clinical response at Week 6 were randomised to receive CZP 400 mg (n = 215) or placebo (n = 210) every 4 weeks from Weeks 6 to 24. The EQ-5D was administered at each visit and converted into utility scores using an established algorithm (Dolan et al., 1995). An estimate of QALYs was made for each patient from the area under the utility curve during the randomisation period of each trial. Mean QALYs and standard deviation (SD) were calculated by treatment group and compared using a Wilcoxon rank sum test. RESULTS: Over the 26-week PRECiSE 1 trial, the mean (SD) QALYs were 0.5456 (0.2993) for CZP and 0.4797 (0.3121) for placebo. Similarly, between Weeks 6 and 26 of PRECiSE 2, the mean (SD) QALYs were 0.4976 (0.2047) in the CZP group versus 0.4286 (0.2171) in the three injection followed by placebo group. A statistically significant gain in QALYs with CZP was observed in both trials: PRECiSE 1 0.0659 (p = 0.001); PRECiSE 2 0.0690 (p = 0.015). CONCLUSION: CZP improved both quality and quantity of remission and response period, as measured by QALYs, significantly more than placebo among patients with CD in two 26-week maintenance trials.
disease-related information, e.g. epidemiology, frequency of interventions (Federal Health Monitoring, German Foundation Organ Transplantation, German Index for Stem Cell Transplantation, Literature). RESULTS: Bavarian demand for blood products of approximately 2,850 units per workday (750,000 units per year) was estimated. Potential blood donors add up to approximately 8,474 million people. Assuming a donation rate of 3% an approx. number of 250,000 donors exist. Most active segment of donors is between 32–56 years. It will be affected by the demographic shift, means a declining population of approximatelt 425,000 people in this segment. Stem cell transplantations (+50% in the last 7 years) and organ transplantations (+15% in 2005) lead to an increasing demand of blood products.

Statistical data show an increasing life expectancy of 5 years until 2030 (male 81.1/female 86.6 years) entailing higher cancer incidence rates (+50% until 2030) affecting blood consumption (20% of all blood products are used in cancer therapies). The German blood market volume for the year 2005 is estimated to be €300 mill. For the Bavarian sub-segment a value of €75 million can be deducted. CONCLUSION: Further research and survey will be necessary to derive strategic recommendations for the blood market participants. Then a dynamic population model will be developed to project future effects on blood demand and supply.

A DETERMINATION OF TOPICS FOR HEALTH TECHNOLOGY ASSESSMENT IN THAILAND
Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand

OBJECTIVES: Health Intervention and Technology Assessment program (HITAP), a newly established Health Technology Assessment (HTA) agency in Thailand, has tried to develop the systematic, transparent, and participatory mechanisms for HTA topic selection. An overall aim of this study was to describe quantitatively and qualitatively progression and findings from HTA topic selection process recently developed by HITAP.

METHODS: The process involved potential users of HTA information namely 1) public health insurers; 2) national health policy makers; and 3) HITAP public funding organizations. In December 2006, these key players were invited to submit the topics needed to be assessed based on their considerations. The submitted topics were reviewed and prioritised by HITAP researchers in January 2007 using several preset criteria. Furthermore, a consultation workshop was conducted and the representatives from those organisations submitted the HTA topics provide justifications and prioritize their own list of top ten HTA topics needed to be assessed in 2007. Results from each organisation were analysed and the final list made by workshop participants were compared with the list made by HITAP researchers.

RESULTS: Fifty-one topics were submitted from ten organisations. However, only 29 distinct HTA topics were met inclusion criteria and then included in the priority setting process. Most topics were pharmaceuticals (51%), medical procedures (24%), medical devices (15%) and health policy (10%). At final, six out of ten topics selected by HITAP researchers were the same as those made by the representatives from public health authorities.

CONCLUSION: Findings from this study illustrated the possibility to make HTA topic selection process to be systematic, transparent and participatory, which would eventually increase the usefulness and credibility of HTA.

BUDGET SILO MENTALITY BEHIND THE FORMER IRON CURTAIN: A CASE STUDY FROM HUNGARY
Boczi I1, Gulácsi L2, Sebestyén A3
1University of Pécs, Pécs, Hungary, 2Corvinus University of Budapest, Budapest, Hungary, 3National Health Insurance Fund Administration, Pécs, Hungary

OBJECTIVES: Between 1994–2006 the budget for pharmaceutical reimbursement of the Hungarian National Health Insurance Fund Administration (OEP), the only health care financing agency in Hungary, showed significant deficit. It means that the actual drug expenditures became much higher at the end of the year as it was originally planned at the beginning of the fiscal year. The aim of the study to analyse the drug budget of the OEP by identifying the pattern of this deficit.

METHODS: Data derived from the financial database of the Hungarian National Health Insurance Fund Administration, covering the period 1994–2006. We analysed the planned and the actual drug budget focusing on the deficit. Deficit was calculated as follows: dividing the gap between the planned and the actual budget by the actual budget.

RESULTS: In each year between 1994–2006 we found a deficit at the drug budget of the OEP. This deficit varied between 2.8% (lowest, 1996) and 36.6% (highest, 2006) of total actual expenditures. We found 4 peaks on the diagram showing the deficit in the following years: 1994 (21.5%), 1998 (32.1%), 2002 (36.6%) and 2006 (30.4%). In each of these years, both national governmental and local elections were held in Hungary.

CONCLUSION: We found deficit in the drug budget of the Hungarian OEP in each year between 1994–2006, however the highest deficit occurred in those years with political elections. Such strong coincidence between political elections and drug budget should be omitted as soon as possible in order to provide a more transparent way of drug reimbursement policy.